Quest Diagnostics has announced a public offering of $550 million ofsenior notes, half of which are due in 2006, with the remaining $275 million due 2011. The size of this placement has been increased from the $500 million originally announced, the company said, adding that it is part of an overall plan to refinance a majority of its existing indebtedness. Merrill Lynch and Credit Suisse First Boston served as lead underwriters.
Quest is the USA's leading provider of diagnostic testing, information and services, and reported revenues of $3.4 billion in 2000.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze